Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

HEMOGLOBIN, a prominent journal published by Taylor & Francis Ltd, serves as a vital resource in the fields of Biochemistry, Clinical Biochemistry, Genetics, and Hematology. Established in 1976, the journal provides a platform for innovative research and review articles that explore the complexities of hemoglobin pathology and related disorders, making significant contributions to our understanding of hematological diseases. With an ISSN of 0363-0269 and an E-ISSN of 1532-432X, HEMOGLOBIN has garnered attention within the academic community, reflected in its category quartiles for 2023, which rank it in the Q3 and Q4 levels across relevant medical and biochemistry categories. Although it operates on a subscription basis rather than as an open-access journal, it remains influential, providing critical insights to researchers, professionals, and students aiming to address the current challenges in blood research and related fields. The journal not only emphasizes high-quality scientific analyses but also seeks to foster collaboration and dialogue among academia and clinical practitioners, ultimately advancing the frontier of knowledge in hemoglobin and hematological research.

Tremor and Other Hyperkinetic Movements is a pioneering open-access journal published by UBIQUITY PRESS LTD, dedicated to advancing the understanding of hyperkinetic movement disorders, including tremors. Since its inception in 2011, the journal has provided a vital platform for researchers, professionals, and students within the fields of neurology and movement disorders to share innovative findings, case studies, and clinical trials. With its contributions spanning from 2012 to 2024, the journal emphasizes high-quality research and fosters collaboration within the medical community. Although it holds a Scopus rank of 156 in the field of Medicine, particularly Cardiology and Cardiovascular Medicine, its value extends beyond metrics, inviting interdisciplinary dialogue about the mechanisms, treatments, and implications of these complex disorders. By offering unrestricted access to its content, Tremor and Other Hyperkinetic Movements ensures that crucial knowledge reaches a global audience, thus enabling advancements in clinical practices and improved patient outcomes.

NEUROCHEMISTRY INTERNATIONAL, published by Pergamon-Elsevier Science Ltd, offers a premier platform for researchers and professionals in the realms of cell biology and cellular and molecular neuroscience. Established in 1980 and continuing its passion for advancing the field, this esteemed journal enhances scientific collaboration with a notable 2023 Q2 ranking in both relevant categories, placing it among the top-tier publications in its discipline with a Scopus rank of 23/97 for Cellular and Molecular Neuroscience. With its focus on groundbreaking research, the journal provides a wealth of vital data and insights that drive forward our understanding of neurochemistry and its implications in health and disease. While not an Open Access journal, NEUROCHEMISTRY INTERNATIONAL is integral for professionals, academics, and students aiming to stay at the forefront of neurobiological research innovations, making significant contributions to both academia and clinical applications.

Annals of Indian Academy of Neurology is a premier open access journal dedicated to advancing the field of Neurology, serving as a vital resource for researchers, healthcare professionals, and students since its inception in 2006. Published by the esteemed Wolters Kluwer Medknow Publications, this journal has established itself within the academic community, boasting a Q3 quartile ranking in clinical neurology according to the 2023 category quartiles and a Scopus rank placing it in the 35th percentile among 400 comparable journals. With a focus on clinical advancements and research innovations in neurology, the journal aims to disseminate high-quality and impactful studies that address the complex challenges faced in the neurological landscape, particularly within the Indian context. The open access model ensures that the latest research is readily accessible to a global audience, thereby promoting collaboration and knowledge sharing within the neurosciences.

Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

Current Behavioral Neuroscience Reports, published by SPRINGERNATURE, stands at the forefront of advancements in the intricate field of behavioral neuroscience. Since its inception in 2014, this journal has steadily garnered attention within academic circles, boasting a commendable ranking among its peers, including a Q3 classification in Behavioral Neuroscience and a Q2 classification in Public Health, Environmental and Occupational Health as of 2023. Although it operates under traditional access models, the journal is committed to disseminating high-quality research that bridges the gap between neuroscience and behavioral studies, appealing to researchers, professionals, and students alike. With a notable E-ISSN of 2196-2979, Current Behavioral Neuroscience Reports facilitates valuable insights that are critical for understanding the underlying mechanisms of behavior and their implications for public health and environmental factors. This journal is essential for those seeking to contribute to a multidisciplinary dialogue that enhances our comprehension of behavioral neuroscience.

ASN Neuro is an esteemed academic journal published by Frontiers Media SA, focusing on critical advancements in the fields of neurology and neuroscience. Since its inception in 2009, it has established itself as an Open Access platform dedicated to fostering the dissemination of knowledge and research findings that address the complexities of the nervous system. With an impressive impact factor and consistently ranking in the top quartiles of its categories—Q1 in Neurology (clinical) and Q2 in Neuroscience (miscellaneous)—ASN Neuro is recognized for its high-quality publications that cater to the evolving challenges in clinical neurology and general neuroscience. Currently, it ranks 68th out of 400 journals in Clinical Neurology and 28th out of 113 in General Neuroscience, affirming its reputable position within the academic community. Researchers, professionals, and students alike are encouraged to contribute to and benefit from this impactful journal as it presents a unique opportunity to engage with cutting-edge research, innovative methodologies, and insightful reviews in the ever-evolving landscape of brain science.

REVIEWS IN THE NEUROSCIENCES is a prestigious peer-reviewed journal published by Walter de Gruyter GmbH, specializing in the multidisciplinary field of neuroscience. With a robust history dating back to 1986 and a converged publishing timeline through to 2024, this journal serves as an essential platform for researchers and professionals who seek to explore the complexities of neuroscience in a rapidly evolving landscape. The journal is currently indexed in Scopus, boasting an impressive rank of #19 out of 113 in the General Neuroscience category, positioning it in the 83rd percentile of academic journals. It is classified within the Q2 quartile, reflecting its significant impact and contribution to the field. While not an Open Access publication, the journal offers extensive access options for institutions and individuals eager to stay informed about the latest findings and advancements in neuroscience. REVIEWS IN THE NEUROSCIENCES aims to provide comprehensive reviews covering a wide range of topics in neuroscience, fostering scholarly discussion and advancing knowledge, making it an invaluable resource for researchers, academics, and students alike.

Clinical Parkinsonism & Related Disorders is a prominent open-access journal published by Elsevier, focused on advancing the understanding and treatment of Parkinson's disease and related neurological conditions. Since its inception in 2019, this journal has aimed to provide a platform for high-quality research, review articles, and clinical studies dedicated to elucidating the complexities of Parkinsonism and its comorbidities. With an E-ISSN of 2590-1125, it has swiftly established its role in the field of clinical neurology, currently ranked in the Q3 quartile for clinical neurology and Q4 for cellular and molecular neuroscience. While its Scopus rankings reflect a competitive landscape, occupying the 241st position in clinical neurology and the 83rd in neuroscience, the journal remains committed to fostering scholarly dialogue and supporting innovative research. Researchers, clinicians, and students will find valuable insights within its pages, contributing to ongoing discourse and the pursuit of effective therapeutic strategies. Access to all articles has been made available since 2019, emphasizing the journal's mission to disseminate knowledge widely and enhance accessibility in the scientific community.